Notably, treatment with an EZH2 inhibitor restores immune cell infiltration and inhibits tumor growth in NSD1-mutant models, highlighting a druggable chromatin crosstalk with potential therapeutic relevance [39]. The gene discussed is NSD1; the disease is neoplasm.